deltatrials
Completed PHASE2 INTERVENTIONAL 2-arm NCT03783910

Efficacy and Safety of GRT9906 Tablets Compared to Placebo in Patients With Fibromyalgia

Cross-over Multiple Dose Study Assessing the Analgesic Efficacy and Safety of Oral GRT9906 Compared to Placebo in Subjects With Primary Fibromyalgia Syndrome

Sponsor: Grünenthal GmbH

Conditions Primary Fibromyalgia
Interventions GRT9906 Placebo
Updated 4 times since 2019 Last updated: Dec 20, 2018 Started: Sep 19, 2005 Primary completion: Oct 31, 2006 Completion: Oct 20, 2006
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Primary Fibromyalgia, this trial is completed. The trial is conducted by Grünenthal GmbH and has accumulated 4 data snapshots since 2005. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2019 – ~Jan 2021 · 24 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 23 months · monthly snapshotCompleted

Change History

4 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jan 2019 — Jan 2021 [monthly]

    Completed PHASE2

    First recorded

Sep 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Grünenthal GmbH
Data source: Grünenthal GmbH

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations